Methods for treating cancer using an immunotoxin

Details for Australian Patent Application No. 2004234191 (hide)

Owner Zangemeister-Wittke, U. Paolo, C. Tschudi, D. Glover, N. Fitsialos, D.

Inventors Zangemeister-Wittke, Uwe; Fitsialos, Dimitri Peter; Tschudi, Dominique Christine; Glover, Nicholas Ronald; Paolo, Claudio Di

Agent Davies Collison Cave

Pub. Number AU-A-2004234191

PCT Pub. Number WO2004/096271

Priority 60/466,608 30.04.03 US

Filing date 30 April 2004

Wipo publication date 11 November 2004

International Classifications

A61K 039/395 Medicinal preparations containing antigens or antibodies - Antibodies

C07K 016/30 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 016/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

8 December 2005 PCT application entered the National Phase

  PCT publication WO2004/096271 Priority application(s): WO2004/096271

4 May 2006 Assignment before Grant

  Zangemeister-Wittke, Uwe; Di Paolo, Claudio; Tschudi, Dominique; Glover, Nicholas; Fitsialos, Dimitri The application has been assigned to University of Zurich

25 November 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004234192-Pharmaceutical compositions comprising cereal beta (1-3) beta (1-4) glucan

2004234190-8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors